2017, Number 6
<< Back
Acta Ortop Mex 2017; 31 (6)
Multidisciplinary meeting on application techniques for restitution of synovial fluid in patients with knee arthritis: update
Gutiérrez-Gómez JJ, Santillán-Barrera E, Velasco-Legoff C, Chávez-Espina LM, Torres-Roldán F, Aldrete-Velasco J
Language: Spanish
References: 32
Page: 319-327
PDF size: 292.34 Kb.
ABSTRACT
In the degradation of articular cartilage, functional limitation and pain —cardinal signs of osteoarthritis— underlies, as a central factor, the quantitative and qualitative alteration of hyaluronic acid, the main component of synovial fluid and cartilage, in a pathophysiological process influenced by a wide variety of risk factors whose impact complicates the disease and radically reduces the quality of life of the patient. Conventional pharmacological management for osteoarthritis is often insufficient. Fortunately, in our days, there are viscosupplements capable of improving, replacing and promoting the endogenous production of degraded hyaluronic acid in osteoarthritis. The use of these compounds requires the adherence to a set of specific techniques, designed for the correct intra-articular infiltration of the viscosupplement without the need to inflict an additional traumatic load on the patient; these techniques —with special reference to the patient affected by knee osteoarthritis (gonarthritis)— are described in this article, which also highlights the criteria for choosing the ideal viscosupplement, the one most similar to hyaluronic acid native in healthy young people, and one whose therapeutic use reports greater clinical benefits in the short and long term.
REFERENCES
Clegg TE, Caborn D, Mauffrey C: Viscosupplementation with hyaluronic acid in the treatment for cartilage lesions: a review of current evidence and future directions. Eur J Orthop Surg Traumatol. 2013; 23(2): 119-24.
Iannitti T, Lodi D, Palmieri B: Intra-articular injections for the treatment of osteoarthritis: focus on the clinical use of hyaluronic acid. Drugs R D. 2011; 11(1): 13-27.
Peña-Ayala AH, Fernández-López JC: Prevalencia y factores de riesgo de la osteoartritis. Reumatol Clin. 2007; 3 Supl E3: S6-12.
Espinosa-Morales R, Arce-Salinas CA, Cajigas-Melgoza JC, Esquivel-Valerio JA, Gutiérrez-Gómez JJ, Martínez-Hernández JL, et al. Reunión multidisciplinaria de expertos en diagnóstico y tratamiento de pacientes con osteoartritis. Actualización basada en evidencias. Med Int Mex. 2013; 29(1): 67-92.
Abud-Mendoza C. Situación actual de los padecimientos reumáticos. Rev Med Hosp Gen Méx. 2001; 64(Supl 1): S7-12.
Arellano-Pérez Vertti RD, Argüello-Astorga JR, Hernández-Terán F, García-Salcedo JJ: Factores de riesgo en osteoartritis de rodilla en una población mexicana de casos y controles. Revista Cubana de Ortopedia y Traumatología. 2013; 27(1): 22-32.
Cardona-Muñoz JI: La viscosuplementación como tratamiento alternativo en la osteoartritis. Ortho-tips. 2012; 8(2): 87-92.
Langworthy MJ, Nelson F, Owens BD: Viscosupplementation for treating osteoarthritis in the military population. Mil Med. 2014; 179(8): 815-20.
Legré-Boyer V: Viscosupplementation: techniques, indications, results. Orthop Traumatol Surg Res. 2015; 101(1 Suppl): S101-8.
Rivera F: Single intra-articular injection of high molecular weight hyaluronic acid for hip osteoarthritis. J Orthop Traumatol. 2016; 17(1): 21-6.
Ricci M, Micheloni GM, Berti M, Perusi F, Sambugaro E, Vecchini E, et al: Clinical comparison of oral administration and viscosupplementation of hyaluronic acid (HA) in early knee osteoarthritis. Musculoskelet Surg. 2017; 101(1): 45-9.
Strand V, McIntyre LF, Beach WR, Miller LE, Block JE: Safety and efficacy of US-approved viscosupplements for knee osteoarthritis: a systematic review and meta-analysis of randomized, saline-controlled trials. J Pain Res. 2015; 8: 217-28.
Henrotin Y, Raman R, Richette P, Bard H, Jerosch J, Conrozier T, et al: Consensus statement on viscosupplementation with hyaluronic acid for the management of osteoarthritis. Semin Arthritis Rheum. 2015; 45(2): 140-9.
Monticone M, Frizziero A, Rovere G, Vittadini F, Uliano D, LA Bruna S, et al: Hyaluronic acid intra-articular injection and exercise therapy: effects on pain and disability in subjects affected by lower limb joints osteoarthritis. A systematic review by the Italian Society of Physical and Rehabilitation Medicine (SIMFER). Eur J Phys Rehabil Med. 2016; 52(3): 389-99.
Mar J, Romero MJ, Arrospiede A, Fidalgo AE, Soler-López B: Análisis de costes del tratamiento con viscosuplementación con ácido hialurónico estabilizado en pacientes con artrosis de rodilla candidatos a implantación de prótesis. Rev Esp Cir Ortop Traumatol. 2013; 57(1): 6-14.
Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther KP, et al: EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2005; 64(5): 669-81.
Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al: American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012; 64(4): 465-74.
American Academy of Orthopaedic Surgeons (AAOS): Treatment of osteoarthritis of the knee, evidence-based guideline. 2nd ed. Illinois, USA: AAOS; 2013.
American Academy of Orthopaedic Surgeons (AAOS): Treatment of osteoarthritis of the knee (non-arthroplasty), full guideline. Illinois, USA: AAOS; 2008.
Wang Y, Hall S, Hanna F, Wluka AE, Grant G, Marks P, et al: Effects of Hylan G-F 20 supplementation on cartilage preservation detected by magnetic resonance imaging in osteoarthritis of the knee: a two-year single-blind clinical trial. BMC Musculoskelet Disord. 2011; 12: 195.
Ayhan E, Kesmezacar H, Akgun I: Intraarticular injections (corticosteroid, hyaluronic acid, platelet rich plasma) for the knee osteoarthritis. World J Orthop. 2014; 5(3): 351-61.
Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, et al: EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003; 62(12): 1145-55.
Aggarwal A, Sempowski IP: Hyaluronic acid injections for knee osteoarthritis. Systematic review of the literature. Can Fam Physician. 2004; 50: 249-56.
Wobig M, Bach G, Beks P, Dickhut A, Runzheimer J, Schwieger G, et al: The role of elastoviscosity in the efficacy of viscosupplementation for osteoarthritis of the knee: a comparison of hylan G-F 20 and a lower-molecular-weight hyaluronan. Clin Ther. 1999; 21(9): 1549-62.
Zhao H, Liu H, Liang X, Li Y, Wang J, Liu C: Hylan G-F 20 versus low molecular weight hyaluronic acids for knee osteoarthritis: a meta-analysis. BioDrugs. 2016; 30(5): 387-96.
McNabb JW: Infiltraciones. Caps. 23, 24. México: Marbán; 2006: 85-93.
Cisneros-Ochoa JR: Cuándo viscosuplementación y cuándo esteroides intraarticulares en el tratamiento de la osteoartritis de rodilla. Ortho-tips. 2012; 8(2): 93-5.
Secretaría de Salud (SS), México. NORMA Oficial Mexicana NOM004SSA32012; Del expediente clínico. Diario Oficial de la Federación (DOF): 15/10/2012.
Genzyme México. Información para prescribir (IPP) Synvisc® (Hilano GF-20). Reg. Núm. 1492C98, SSA.
Sanfélix-Genovés J, Giner-Ruiz V, Millán-Soria J, Fuertes-Fortea A: Capítulo I: Infiltraciones articulares y de tejidos blandos. Aspectos generales. En: Sanfélix-Genovés J, Giner-Ruiz V, Millán-Soria J, Fuertes-Fortea A: Manual de infiltraciones en atención primaria. Valenciana, España: Generalitat; 2007: 9-16. Disponible en: http://publicaciones.san.gva.es/publicaciones/documentos/V.5192-2007.pdf
Hermosa-Hernán JC, Pascual-González R: Técnicas de infiltración en aparato locomotor. Rodilla. AMF. 2016; 12(10): 596-609.
Conrozier T, Patarin J, Mathieu P, Rinaudo M: Steroids, lidocain and ioxaglic acid modify the viscosity of hyaluronic acid: in vitro study and clinical implications. Springerplus. 2016; 5: 170.